$Moderna, Inc.(MRNA)$ The regulatory submission for the melanoma vaccine is getting close, possibly as early as next month. Data should be out soon, and approvals by early 2027 would set things up for a solid launch.
Readouts from other cancer products could add more momentum for the oncology platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments